Abstract:Cerebral malaria is associated with the circulating levels of tumour necrosis factor alpha (TNF-α) and transforming growth factor β (TGF-β), but association between these two cytokines and implications in splenocyte apoptosis remain largely obscured. We have evaluated the outcome of TGF-β and TNF-α production in the context of splenocyte apoptosis during Plasmodium berghei ANKA (PbA) infection. Blood-stage PbA infection confirmed blood-brain barrier disruption, disarray of white pulp, increase in percentage of… Show more
“…The histological alterations in splenic tissue sections after infection with live P. chabaudi presented as hypertrophied white pulp, has been reported previously (Achtman et al, 2003). In the current study, live P. chabaudi infection resulted in an increase in apoptotic cell death in splenic tissue sections and this is in agreement with previous studies (Keswani and Bhattacharyya, 2013). Nevertheless, the gamma irradiated P. chabaudi infected group presented, to some extent, a similar picture to that of the control group.…”
Authors' Contributions MA designed the study and performed the practical work. FAG and SA analyzed the data. GB performed the statistical analysis. SA and AE wrote the article. SA supervised the work.
“…The histological alterations in splenic tissue sections after infection with live P. chabaudi presented as hypertrophied white pulp, has been reported previously (Achtman et al, 2003). In the current study, live P. chabaudi infection resulted in an increase in apoptotic cell death in splenic tissue sections and this is in agreement with previous studies (Keswani and Bhattacharyya, 2013). Nevertheless, the gamma irradiated P. chabaudi infected group presented, to some extent, a similar picture to that of the control group.…”
Authors' Contributions MA designed the study and performed the practical work. FAG and SA analyzed the data. GB performed the statistical analysis. SA and AE wrote the article. SA supervised the work.
“…Different doses of SB431542 (2, 5, 10, and 20 mg/kg BW) were tested where 20 mg/kg BW was effective at decreasing TGF‐β concentration, but induced a higher mortality rate, indicating a possible toxic effect (data not shown). Therefore, we selected a maximal dose of 10 mg/kg BW in the following experiments (Keswani and Bhattacharyya, ). We standardized that at 10 mg/kg BW conc., SB431542 blocks TGF‐β expression for 48–72 h in control C57BL/6 mice after receiving single 100 μL i.p.…”
Idiopathic pulmonary fibrosis (IPF) is a deadly, progressive lung disease with very few treatment options till now. Bleomycin-induced pulmonary fibrosis (BIPF) is a commonly used mice model in IPF research. TGF-β1 has been shown to play a key role in pulmonary fibrosis (PF). Dendritic cell (DC) acts as a bridge between innate and adaptive immune systems. The coexistence of chronic inflammation sustained by mature DCs with fibrosis suggests that inflammatory phenomenon has key importance in the pathogenesis of pulmonary fibrosis. Here, we investigated the modulation of DCs phenotypic maturation, accumulation in lung tissue, and expression of other lung DC subsets in respect to TGF-β in PF. First, we established BIPF model in mice and blocked TGF-β expression by the use of inhibitor SB431542. Accumulation of lung CD11c+ DCs is significantly higher in both inflammatory and fibrotic phases of the disease but that percentages got reduced in the absence of TGF-β. TGF-β initiates up-regulation of costimulatory molecules CD86 and CD80 in the inflammatory phases of the disease but not so at fibrotic stage. Expression of lung DC subset CD11c+CD103+ is significantly increased in inflammatory phase and also in fibrotic phase of BIPF. Blocking of TGF-β causes decreased expression of CD11c+CD103+ DCs. Another important lung DC subset CD11c+CD11b+ expression is suppressed by the absence of TGF-β after bleomycin administration. CD11c+CD103+ DCs might have anti-inflammatory as well as anti-fibrotic nature in PF. All these data demonstrate differential modulation of CD11c+ lung DCs by TGF-β in experimental PF.
“…On the other hand, P. berghei NK65-infected mice showed enhanced production of LT-α and several chemokines (CXCL-9/MIG, CCL-2/MCP-1, CCL-3/MIP-1α and CCL-5/RANTES), but no neurological symptoms [47,122]. A complementary study performed on the same model proposed a concurrent role for Transforming Growth Factor-β (TGF-β) and TNF-α in promoting splenocyte apoptosis [123]. …”
Cerebral malaria (CM) is a life-threatening complication of falciparum malaria, associated with high mortality rates, as well as neurological impairment in surviving patients. Despite disease severity, the etiology of CM remains elusive. Interestingly, although the Plasmodium parasite is sequestered in cerebral microvessels, it does not enter the brain parenchyma: so how does Plasmodium induce neuronal dysfunction? Several independent research groups have suggested a mechanism in which increased blood–brain barrier (BBB) permeability might allow toxic molecules from the parasite or the host to enter the brain. However, the reported severity of BBB damage in CM is variable depending on the model system, ranging from mild impairment to full BBB breakdown. Moreover, the factors responsible for increased BBB permeability are still unknown. Here we review the prevailing theories on CM pathophysiology and discuss new evidence from animal and human CM models implicating BBB damage. Finally, we will review the newly-described role of matrix metalloproteinases (MMPs) and BBB integrity. MMPs comprise a family of proteolytic enzymes involved in modulating inflammatory response, disrupting tight junctions, and degrading sub-endothelial basal lamina. As such, MMPs represent potential innovative drug targets for CM.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.